Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04318938

Recruitment Status : Recruiting

First Posted : March 24, 2020

Last Update Posted : November 14, 2022

See Contacts and Locations

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	December 31, 2025
Estimated Study Completion Date :	December 31, 2025

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Christopoulos P, Bozorgmehr F, Bruckner L, Chung I, Krisam J, Schneider MA, Stenzinger A, Eickhoff R, Mueller DW, Thomas M. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. BMC Cancer. 2021 Jun 28;21(1):743. doi: 10.1186/s12885-021-08460-w.

To Top